NO951762L - Stabilt preparat for behandling av blodkoagulasjonssykdommer, omfattende et aktivt koagulasjonsfremmende stoff - Google Patents

Stabilt preparat for behandling av blodkoagulasjonssykdommer, omfattende et aktivt koagulasjonsfremmende stoff

Info

Publication number
NO951762L
NO951762L NO951762A NO951762A NO951762L NO 951762 L NO951762 L NO 951762L NO 951762 A NO951762 A NO 951762A NO 951762 A NO951762 A NO 951762A NO 951762 L NO951762 L NO 951762L
Authority
NO
Norway
Prior art keywords
treatment
blood coagulation
coagulation
active
disorders
Prior art date
Application number
NO951762A
Other languages
English (en)
Other versions
NO951762D0 (no
Inventor
Johann Eibl
Hans Peter Schwarz
Jurgen Siekmann
Peter Turecek
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of NO951762D0 publication Critical patent/NO951762D0/no
Publication of NO951762L publication Critical patent/NO951762L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det beskrives et stabilt pre- parat for behandling av blodkoagula- sjonssykdommer som omfatter en aktiv, koagulasjonsfremmende substans, som f.eks. en aktivert koagulasjonsfaktor og eventuelt andre proteiner, som er bundet i eller på lipidvesikler. Pre- paratene kan gjøres tilgjengelige i en virusinaktivert form. Oppfinnelsen gjelder også anvendelsen av lipidvesikler som er bundet til trombocyttlignende blod- koagulasjonsfaktorer for fremstilling av et preparat for behandling av blod- koagulasjonssykdommer som er forbundet med en mangel på aktiverte trombocyt- ter. Videre gjelder oppfinnelsen fremgangsmåter for fremstilling av pre- parater for behandling av blodkoagula- sj onssykdommer.
NO951762A 1994-05-06 1995-05-05 Stabilt preparat for behandling av blodkoagulasjonssykdommer, omfattende et aktivt koagulasjonsfremmende stoff NO951762L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4416180A DE4416180C2 (de) 1994-05-06 1994-05-06 Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen und Verfahren zur Herstellung dieses Präparats

Publications (2)

Publication Number Publication Date
NO951762D0 NO951762D0 (no) 1995-05-05
NO951762L true NO951762L (no) 1995-11-07

Family

ID=6517576

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951762A NO951762L (no) 1994-05-06 1995-05-05 Stabilt preparat for behandling av blodkoagulasjonssykdommer, omfattende et aktivt koagulasjonsfremmende stoff

Country Status (7)

Country Link
EP (1) EP0680763A3 (no)
JP (1) JPH0840928A (no)
AT (1) ATA77095A (no)
CA (1) CA2148672A1 (no)
DE (1) DE4416180C2 (no)
FI (1) FI952170A7 (no)
NO (1) NO951762L (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
HUP9700603A3 (en) * 1996-03-20 2001-08-28 Baxter Ag Pharmaceutical preparation for the treatment of blood coagulation disorders
WO1999066939A1 (en) * 1998-06-23 1999-12-29 Marder Victor J Phospholipid vesicle-tissue factor complex preparations and methods of making and using same
US7056529B2 (en) * 2002-05-14 2006-06-06 University Of Louisville Research Foundation, Inc. Direct cellular energy delivery system
JP5160534B2 (ja) * 2006-03-30 2013-03-13 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 低免疫原性および長時間循環性タンパク質−脂質複合体の組成物
KR102271515B1 (ko) 2015-02-06 2021-07-05 광저우 바이오실 바이오테크 캄파니 리미티드 트롬빈의 제조 방법
JP7395353B2 (ja) * 2018-10-17 2023-12-11 東レ株式会社 止血材
JP6772322B2 (ja) * 2019-03-01 2020-10-21 コウシュウ・バイオシール・バイオテック・カンパニー・リミテッドＧｕａｎｇｚｈｏｕ Ｂｉｏｓｅａｌ Ｂｉｏｔｅｃｈ Ｃｏ．， Ｌｔｄ． トロンビンの調製のための方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5770814A (en) * 1980-10-17 1982-05-01 Isamu Horikoshi Oral preparation of blood clotting eighth factor
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
GB2129685B (en) * 1982-11-11 1985-11-13 Nat Biolog Standards Board Anti-haemophilic compositions
US4721618A (en) * 1983-06-27 1988-01-26 Queen's University At Kingston Method for controlling bleeding
US4610880A (en) * 1983-06-27 1986-09-09 Queen's University At Kingston Composition for controlling hemophilia in mammals
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
WO1990003808A1 (en) * 1988-10-07 1990-04-19 The Liposome Company, Inc. Heat treating liposomes
AU5959990A (en) * 1989-08-14 1991-04-03 Queen's University At Kingston Method for stimulating fibrinolytic effect
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
CA2168671C (en) * 1993-08-06 2007-04-10 Yechezkel Barenholz A method for high loading of vesicles with biopolymeric substances
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen

Also Published As

Publication number Publication date
DE4416180A1 (de) 1995-11-09
CA2148672A1 (en) 1995-11-07
FI952170A0 (fi) 1995-05-05
FI952170L (fi) 1995-11-07
DE4416180C2 (de) 1997-08-14
JPH0840928A (ja) 1996-02-13
ATA77095A (de) 2002-04-15
EP0680763A2 (en) 1995-11-08
NO951762D0 (no) 1995-05-05
FI952170A7 (fi) 1995-11-07
EP0680763A3 (en) 1998-01-28

Similar Documents

Publication Publication Date Title
NO951761L (no) Stabilt preparat for behandling av blodkoagulasjonssykdommer
CA1329760C (en) Plasma and recombinant protein formulations in high ionic strength media
Anner et al. A reconstituted Na++ K+ pump in liposomes containing purified (Na++ K+-ATPase from kidney medulla
BR0206985A (pt) Anticorpos modificados e métodos de uso
DE69530763D1 (de) Antikörper gegen e-selektin
GEP19981289B (en) Method for Preparing Preserved Medicinal Means Containing Human Protein and Medicinal Means
UA41297C2 (uk) Похідні індолу, фармацевтична композиція і спосіб лікування
NO166943C (no) Analogifremgangsmaate for fremstilling av enzymresistente immunomodulerende peptider.
PT758248E (pt) Formulacoes para o factor ix
WO1998026747A3 (en) Superantigen based methods and compositions for treatment of diseases
NO20013701D0 (no) HER-2/neu-fusjonsproteiner
DK0865294T3 (da) Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater
BRPI0109494B8 (pt) muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii
ATE140388T1 (de) Zusammensetzungen enthaltend omega conotoxin peptide derivate und deren verwendung zur behandlung von ischämie-artigen neuronalen schädigungen
WO1996025947A3 (en) Induction of e-selectin for targetting therapeutic agents
MX9603925A (es) Combinaciones de anticoagulantes y proteinas activas tromboliticamente, y usos de las mismas.
DE69703689D1 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
DE69726759D1 (de) Cytopatische viren zur therapie und prophylaxe der neoplasie
DE69410254D1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
ES549115A0 (es) Procedimiento de producir preparaciones para tratar pacien- tes de hemofilia a inhibidores
FR2857267B1 (fr) Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
ATE220912T1 (de) Herstellung von st1435 enthaltenden pharmazeutischen zusammensetzungen zur topischen verwendung
DK188680A (da) Fremgangsmaade til fremstilling af 6-substituerede 11-alkylenmorphantridiner
ES2220256T1 (es) Albumina humana terapeutica con baja actividad para la fijacion de aluminio.